iTeos Therapeutics’ (ITOS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a research note released on Friday,Benzinga reports. The brokerage currently has a $21.00 price target on the stock.

Separately, Wedbush reiterated an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research report on Thursday.

iTeos Therapeutics Stock Down 3.4 %

iTeos Therapeutics stock opened at $7.68 on Friday. The business’s 50-day moving average price is $8.74 and its 200 day moving average price is $12.92. The firm has a market cap of $280.58 million, a price-to-earnings ratio of -2.44 and a beta of 1.37. iTeos Therapeutics has a 52 week low of $7.44 and a 52 week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. Equities analysts expect that iTeos Therapeutics will post -3.46 EPS for the current year.

Insider Buying and Selling

In other iTeos Therapeutics news, CFO Matthew Gall bought 5,000 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was acquired at an average price of $7.73 per share, with a total value of $38,650.00. Following the completion of the acquisition, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at $505,766.17. This represents a 8.27 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 12.50% of the stock is owned by insiders.

Hedge Funds Weigh In On iTeos Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Clearline Capital LP acquired a new stake in iTeos Therapeutics in the 2nd quarter valued at about $2,328,000. Algert Global LLC grew its position in shares of iTeos Therapeutics by 92.0% in the third quarter. Algert Global LLC now owns 256,139 shares of the company’s stock valued at $2,615,000 after purchasing an additional 122,730 shares in the last quarter. Candriam S.C.A. acquired a new stake in shares of iTeos Therapeutics in the second quarter valued at approximately $7,558,000. Dimensional Fund Advisors LP lifted its position in iTeos Therapeutics by 14.8% during the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock worth $13,481,000 after buying an additional 117,159 shares in the last quarter. Finally, Readystate Asset Management LP boosted its stake in iTeos Therapeutics by 97.2% during the third quarter. Readystate Asset Management LP now owns 169,819 shares of the company’s stock worth $1,734,000 after buying an additional 83,700 shares during the last quarter. 97.16% of the stock is owned by hedge funds and other institutional investors.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.